Evaluating a new treatment for Polycythemia Vera

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a new drug, 9MW3011, in patients diagnosed with Polycythemia Vera (PV) who have not responded to or cannot tolerate standard treatments like hydroxyurea or Interferon alpha. The study will involve multiple dose cohorts, with each cohort consisting of 8 subjects receiving the drug via intravenous infusion. Decisions regarding further dose escalation and case expansion will be based on the collected safety and pharmacokinetic-pharmacodynamic data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female patients aged 18 years or older at the time of screening.
2. A confirmed diagnosis of PV according to the revised 2016 World Health Organization criteria and are resistant to or intolerant of hydroxyurea or Interferon alpha.
3. Have a treatment history for PV with resistance or intolerance to hydroxyurea or Interferon alpha.
4. Subjects receiving hydroxyurea, Interferon alpha, or ruxolitinib must complete a washout period before administration of the investigational drug.
5. Must agree to adhere to appropriate contraception requirements during the study period.
6. All female subjects with fertility capacity tested negative for blood pregnancy.
7. Voluntarily participate in clinical trials and agrees to participate in the study by giving written informed consent.

Exclusion Criteria:

1. The spleen is palpable at least 5 centimeters below the left costal margin upon palpation at baseline.
2. Heart failure, unstable angina pectoris, myocardial infarction, and other thrombotic diseases within the 6 months prior to screening.
3. Abnormal QTc interval of electrocardiogram within the 6 months prior to screening.
4. Uncontrolled hypertension prior to screening.
5. Any non-PV myeloproliferative neoplasms (MPN).
6. Blast cells and blast granulocytes in the peripheral blood within the 3 months prior to screening.
7. Hematological indicators do not meet the requirements at the time of screening.
8. Known positive for active hepatitis B, hepatitis C, syphilis or human immunodeficiency virus (HIV) infection.
9. History of invasive malignancies within the last 5 years.
10. Severe infection or uncontrolled active infection.
11. Other hematological and lymphatic system diseases or any diseases causing hemolysis or erythrocyte instability.
12. Other systemic diseases or a family history of systemic diseases, may affect the subject's safety or any other diseases and physiological conditions that may affect the results of the study, judged by the investigator.
13. Specific history of allergies.
14. Subjects who have used monoclonal antibodies within the 6 months prior to screening.
15. Patients who have received vaccinations within 6 weeks prior to screening.
16. Subjects who have received other antitumor therapeutic drugs for PV prior to screening.
17. Chronic diseases requiring treatment with systemic glucocorticoids or other immunosuppressants.
18. History of drug abuse or illicit drug use within 3 months prior to screening.
19. Participation in other clinical trials within 3 months prior to screening.
20. Planned elective surgery during the study.
21. History of surgery within 3 months prior to screening.
22. Intolerable iron deficiency-related symptoms judged by the investigator prior to the first dosing.
23. Pregnant or lactating females; women of reproductive age who are not using effective contraception.
24. Individuals directly associated with the research and/or their immediate family members.
25. Other factors which may potentially affect the assessment of the study results by the investigator.

Where it's running

• Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• The First Affiliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Recruiting
• Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Tianjin, Tianjin Municipality, China Recruiting
• The Second Hospital of Tianjin Medical University
  Tianjin, Tianjin Municipality, China Recruiting
• The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Sapablursen added to standard care for people with polycythemia vera

  This trial will test whether adding sapablursen to standard therapy can reduce the need for phlebotomy in people with polycythemia vera who remain phlebotomy-dependent.

  Recruiting at 38 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Orange, California and 37 other locations · NCT07429266

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• ELN multicenter analysis of phenotypic evolution and clinical outcomes

  This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.

  Recruiting at 10 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Rochester, Minnesota and 23 other locations · NCT07203768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.